CVSI
CV Sciences, Inc. operates as a life science company in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The Consumer Products segment develops, manufactures, and markets plant-based dietary supplements and hemp-based cannabidiol (CBD) products under the PlusCBD, ProCBD, HappyLane, CV Acute, CV Defense, and PlusCBD Pet brand names in various health care sectors, including nutraceutical, beauty care, specialty foods, and pet products. It sells its products through its websites, internet sales, elect distributors, brick and mortar retailers, and select e-tailers. The Specialty Pharmaceutical segment focuses on developing and commercializing cannabinoids to treat medical indications. This segment is developing drug candidate CVSI-007 that combines CBD and nicotine in treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.00 | $3M | $98,000 |
| 2025 Q4 | -0.00 | $3M | -$363,000 |
| 2025 Q3 | -0.00 | $3M | -$270,000 |
| 2025 Q2 | -0.00 | $4M | $238,000 |
| 2025 Q1 | -0.00 | $4M | -$121,000 |
| 2024 Q4 | -0.00 | $4M | -$182,000 |
| 2024 Q3 | -0.00 | $4M | -$122,000 |
| 2024 Q2 | -0.00 | $4M | -$57,000 |